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Vitamin D and chronic disease prevention
Multiple meta-analyses but still no magic bullet
Paul Welsh British Heart Foundation intermediate fellow, Naveed Sattar professor of metabolic
medicine
Institute of Cardiovascular and Medical Science, British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow
G12 8TA, UK
Vitamin D “deficiency” (circulating 25-hydroxyvitamin D
concentration <30 nmol/L) has been linked to a remarkable
array of chronic diseases, including bone mineral disease,
autoimmunity, cancer, diabetes, and cardiovascular outcomes.1
So plentiful are vitamin D’s putative mechanistic actions that
it has been whimsically invoked as an explanation for why good
triumphs over evil in JRR Tolkien’s The Hobbit.2 Parody aside,
the vitamin D literature comprises a minefield of observational
data and mixed quality evidence from predominately small
trials. Appropriate interpretation of the data is further muddied
by seemingly endless media reports suggesting vitamin D as a
panacea for chronic disease.3 4
Against this backdrop, two new papers bravely attempt to make
sense of the existing data. Theodoratou and colleagues (doi:10.
1136/bmj.g2035) highlight differences between observational
data (relating circulating 25-hydroxyvitamin D to outcomes)
and randomised controlled trials of supplementation.5 Of a
remarkable 137 different outcomes reportedly linked to
25-hydroxyvitamin D, only 10 had also been tested in trials,
and only one (birth weight) had apparently concordant evidence
of “benefit” from observational studies and trials. This pattern
of findings should ring alarm bells; observational epidemiology
extolled the virtues of antioxidant vitamins, only for major trials
of vitamins E and C and β carotene to show null, or even some
harmful, effects of supplementation on a range of outcomes.6-8
This highlights the often underestimated problems of
confounding and reverse causality that can lead to premature
causal inferences in observational studies.9 Such factors are
potentially even more applicable to vitamin D; circulating
concentrations can be lowered not only by lack of sun exposure
(itself linked to many lifestyle circumstances) but also by
inflammation, smoking, obesity, and poor diet.10-12Consequently,
observational data linking 25-hydroxyvitamin D concentrations
to any outcome can only ever be hypothesis generating.
Taking a different approach, Chowdhury and colleagues (doi:10.
1136/bmj.g1903) provide a newmeta-analysis of observational
and trial data relating vitamin D (given alone as either the D2
or D3 preparation), to risk of all cause mortality.
13 Their
observational analyses unsurprisingly confirmed low
25-hydroxyvitamin D to be associated with elevated risk of
multiple adverse outcomes. However, their analysis of trials
provides the most noteworthy finding: whereas D2
supplementation did not seem to reduce all cause mortality
(relative risk 1.04, 95% confidence interval 0.97 to 1.11), D3
supplementation did (0.89, 0.80 to 0.99). A previous Cochrane
review also reported a reduction in all cause mortality with the
use of D3, albeit of lower magnitude (relative risk 0.94, 0.91 to
0.98).14
The apparent degree of benefit from D3 in the new
analyses—11% lower mortality—seems remarkable, but before
these results are taken as a green light for widespread D3
supplementation, several limitations must be considered. Firstly,
14 trials contributed to the D3 meta-analysis, totalling only 13
637 participants, and six of these were scored as being at high
risk of bias. Contrast this to meta-analyses of large scale
antihypertensive and statin trials,15 16 which have an order of
magnitude more participants, generally in better quality studies.
Secondly, indicative of inherent uncertainty, different authors
have reached somewhat differing conclusions despite exhaustive
analysis on apparently overlapping datasets.5 14 17
Thirdly, the four studies (n=10 197) that contributed the most
power to the D3 trial meta-analyses were conducted in older
people and had fractures as the primary outcome. If we accept
a small benefit of vitamin D supplementation on risk of fracture,
although even this has been challenged,5 17 18 the observed
reduction in mortality may have been secondary to avoidance
of in-hospital complications and loss of independence in later
life. Any potential reduction in mortality may therefore not be
generalisable to middle aged populations. Fourthly, genetic
studies investigating the causal role of vitamin D in chronic
disease are sparse and inconclusive. Finally, and perhaps most
importantly, vitamin D supplementation may not be without
harm. Theodoratou and colleagues highlight an increased risk
of hypercalcaemia in chronic kidney disease,5 a side effect that
can also occur in people without renal disease.19 20 Thus, larger
studies are still needed to rule out potential adverse effects.
We suggest three take home messages from these two new
studies. Firstly, healthcare professionals should treat all
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observational data cautiously, as existing disease and associated
risk factors may cause, rather than be a consequence of, low
circulating 25-hydroxyvitamin D. Secondly, before widespread
supplementation can be considered, new trial data are needed
with a focus on potential risks as well as benefits; further
reanalysis of existing data will not suffice. Fortunately, new
trials are under way—for example, VITAL,21which has recruited
26 000 men and women and randomised them to 2000 IU D3,
omega-3 fatty acid, or placebo in a two by two factorial design.
Its primary outcomes will be cancer, coronary heart disease,
and stroke, and it is due to report around 2017. VITALwill also
be able to assess whether any benefits of D3 vary by baseline
25-hydroxyvitamin D concentrations. This study alone will
therefore substantially increase the available D3 trial evidence
base, and, importantly, extend it to younger people.
Finally, while we wait for results of major trials, clinicians
should avoid costly measurement of 25-hydroxyvitamin D in
asymptomatic patients outside of bone disease related
conditions.22 Some may argue that supplementing those who
are apparently “deficient” is cheap, but patients may gain false
reassurance from prescription of a “protective” tablet. To
improve health and prevent chronic disease, we should stick to
what is proven: encourage better lifestyles in general and target
established risk factors in people at elevated risk.
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